Sanofi (SNYNF)
USD 98.65
(0.0%)
USD 98.65
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 14.34 Billion EUR | -14.4% |
| 2022 | 16.76 Billion EUR | -11.61% |
| 2021 | 18.96 Billion EUR | -8.29% |
| 2020 | 20.67 Billion EUR | -2.09% |
| 2019 | 21.11 Billion EUR | -4.04% |
| 2018 | 22 Billion EUR | 53.62% |
| 2017 | 14.32 Billion EUR | -14.8% |
| 2016 | 16.81 Billion EUR | 28.18% |
| 2015 | 13.11 Billion EUR | -1.19% |
| 2014 | 13.27 Billion EUR | 27.48% |
| 2013 | 10.41 Billion EUR | -2.85% |
| 2012 | 10.71 Billion EUR | -14.24% |
| 2011 | 12.49 Billion EUR | 86.69% |
| 2010 | 6.69 Billion EUR | 12.31% |
| 2009 | 5.96 Billion EUR | 42.85% |
| 2008 | 4.17 Billion EUR | 11.58% |
| 2007 | 3.74 Billion EUR | -16.87% |
| 2006 | 4.49 Billion EUR | -5.22% |
| 2005 | 4.74 Billion EUR | -45.01% |
| 2004 | 8.63 Billion EUR | 16124.8% |
| 2003 | 53.2 Million EUR | -17.9% |
| 2002 | 64.8 Million EUR | -45.54% |
| 2001 | 119 Million EUR | -1.65% |
| 2000 | 121 Million EUR | -11.68% |
| 1999 | 137 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 12.5 Billion EUR | 0.0% |
| 2024 Q1 | - EUR | -100.0% |
| 2023 Q3 | - EUR | -100.0% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 Q2 | 16.08 Billion EUR | 0.0% |
| 2023 Q4 | 14.34 Billion EUR | 0.0% |
| 2023 FY | 14.34 Billion EUR | -14.4% |
| 2022 Q4 | 16.76 Billion EUR | 0.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 FY | 16.76 Billion EUR | -11.61% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q2 | 17.94 Billion EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q4 | 18.96 Billion EUR | 0.0% |
| 2021 Q2 | 19.17 Billion EUR | 0.0% |
| 2021 Q3 | - EUR | -100.0% |
| 2021 FY | 18.96 Billion EUR | -8.29% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 20.67 Billion EUR | 0.0% |
| 2020 Q2 | 21.35 Billion EUR | 0.0% |
| 2020 FY | 20.67 Billion EUR | -2.09% |
| 2020 Q3 | - EUR | -100.0% |
| 2019 Q4 | 21.11 Billion EUR | 0.0% |
| 2019 Q3 | - EUR | -100.0% |
| 2019 Q2 | 22.04 Billion EUR | 0.0% |
| 2019 Q1 | - EUR | -100.0% |
| 2019 FY | 21.11 Billion EUR | -4.04% |
| 2018 Q3 | - EUR | -100.0% |
| 2018 Q1 | 21.46 Billion EUR | 49.8% |
| 2018 FY | 22 Billion EUR | 53.62% |
| 2018 Q4 | 22 Billion EUR | 0.0% |
| 2018 Q2 | 22.78 Billion EUR | 6.19% |
| 2017 FY | 14.32 Billion EUR | -14.8% |
| 2017 Q2 | 15.18 Billion EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q4 | 14.32 Billion EUR | 0.0% |
| 2017 Q1 | - EUR | -100.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 16.81 Billion EUR | 28.18% |
| 2016 Q4 | 16.81 Billion EUR | 0.0% |
| 2016 Q3 | - EUR | -100.0% |
| 2016 Q2 | 14.85 Billion EUR | 0.0% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 FY | 13.11 Billion EUR | -1.19% |
| 2015 Q3 | - EUR | -100.0% |
| 2015 Q2 | 10.77 Billion EUR | 0.0% |
| 2015 Q4 | 13.11 Billion EUR | 0.0% |
| 2014 Q1 | - EUR | -100.0% |
| 2014 Q4 | 13.27 Billion EUR | 0.0% |
| 2014 Q2 | 10.11 Billion EUR | 0.0% |
| 2014 Q3 | - EUR | -100.0% |
| 2014 FY | 13.27 Billion EUR | 27.48% |
| 2013 Q3 | - EUR | -100.0% |
| 2013 Q4 | 10.41 Billion EUR | 0.0% |
| 2013 FY | 10.41 Billion EUR | -2.85% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q2 | 10.68 Billion EUR | 0.0% |
| 2012 FY | 10.71 Billion EUR | -14.24% |
| 2012 Q4 | 10.71 Billion EUR | 0.0% |
| 2012 Q2 | 10.27 Billion EUR | 0.0% |
| 2011 Q4 | 12.49 Billion EUR | 0.0% |
| 2011 Q2 | 13.28 Billion EUR | 0.0% |
| 2011 FY | 12.49 Billion EUR | 86.69% |
| 2010 Q2 | 7.06 Billion EUR | 0.0% |
| 2010 Q4 | 6.69 Billion EUR | 0.0% |
| 2010 FY | 6.69 Billion EUR | 12.31% |
| 2009 Q4 | 5.96 Billion EUR | 0.0% |
| 2009 Q2 | 6.98 Billion EUR | 0.0% |
| 2009 FY | 5.96 Billion EUR | 42.85% |
| 2008 Q4 | 4.17 Billion EUR | 0.0% |
| 2008 FY | 4.17 Billion EUR | 11.58% |
| 2008 Q2 | 4.28 Billion EUR | 0.0% |
| 2007 Q4 | 3.74 Billion EUR | 0.0% |
| 2007 FY | 3.74 Billion EUR | -16.87% |
| 2007 Q2 | 4.18 Billion EUR | 0.0% |
| 2006 Q4 | 4.49 Billion EUR | 0.0% |
| 2006 Q2 | 3.72 Billion EUR | 0.0% |
| 2006 FY | 4.49 Billion EUR | -5.22% |
| 2005 Q4 | 4.74 Billion EUR | 0.0% |
| 2005 Q2 | 7.11 Billion EUR | 0.0% |
| 2005 FY | 4.74 Billion EUR | -45.01% |
| 2004 Q4 | 8.63 Billion EUR | 0.0% |
| 2004 FY | 8.63 Billion EUR | 16124.8% |
| 2004 Q2 | 49.19 Million EUR | 0.0% |
| 2003 Q2 | 59.09 Million EUR | 0.0% |
| 2003 FY | 53.2 Million EUR | -17.9% |
| 2003 Q4 | 53.2 Million EUR | 0.0% |
| 2002 FY | 64.8 Million EUR | -45.54% |
| 2002 Q4 | 64.8 Million EUR | 0.0% |
| 2002 Q2 | 68.44 Million EUR | 0.0% |
| 2001 FY | 119 Million EUR | -1.65% |
| 2000 FY | 121 Million EUR | -11.68% |
| 1999 FY | 137 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 35.76% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 62.426% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -13301.147% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 28.387% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -73884.514% |